title: Animal models of enterovirus 71 infection: applications and limitations.
abstract: Human enterovirus 71 (EV71) has emerged as a neuroinvasive virus that is responsible for several outbreaks in the Asia-Pacific region over the past 15 years. Appropriate animal models are needed to understand EV71 neuropathogenesis better and to facilitate the development of effective vaccines and drugs. Non-human primate models have been used to characterize and evaluate the neurovirulence of EV71 after the early outbreaks in late 1990s. However, these models were not suitable for assessing the neurovirulence level of the virus and were associated with ethical and economic difficulties in terms of broad application. Several strategies have been applied to develop mouse models of EV71 infection, including strategies that employ virus adaption and immunodeficient hosts. Although these mouse models do not closely mimic human disease, they have been applied to determine the pathogenesis of and treatment and prevention of the disease. EV71 receptor-transgenic mouse models have recently been developed and have significantly advanced our understanding of the biological features of the virus and the host-parasite interactions. Overall, each of these models has advantages and disadvantages, and these models are differentially suited for studies of EV71 pathogenesis and/or the pre-clinical testing of antiviral drugs and vaccines. In this paper, we review the characteristics, applications and limitation of these EV71 animal models, including non-human primate and mouse models.
authors.forename: Ya-Fang
authors.initials: YF
authors.lastname: Wang
authors.affiliation: Center of Infectious Disease and Signaling Research, Collage of Medicine, National Cheng Kung University, Tainan, Taiwan. dckyu@mail.ncku.edu.tw.
authors.forename: Chun-Keung
authors.initials: CK
authors.lastname: Yu
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000008:administration & dosage / Q000276:immunology; D000998:Antiviral Agents / Q000008:administration & dosage*; D004195:Disease Models, Animal; D029821:Enterovirus A, Human / Q000187:drug effects* / Q000235:genetics* / Q000472:pathogenicity; D004769:Enterovirus Infections / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D006790:Host-Parasite Interactions / Q000235:genetics; D006801:Humans; D051379:Mice; D014779:Virus Replication / Q000187:drug effects
chemical_list: D000914:Antibodies, Viral; D000998:Antiviral Agents
references.citation: Arch Virol. 1978;56(3):257-61
references.pmid: 205198
references.citation: Pediatr Infect Dis J. 1995 Dec;14(12):1095-100
references.pmid: 8745025
references.citation: Lab Invest. 2011 Sep;91(9):1337-50
references.pmid: 21555996
references.citation: J Virol. 2010 Jan;84(1):661-5
references.pmid: 19864378
references.citation: PLoS One. 2013;8(2):e55536
references.pmid: 23390538
references.citation: Acta Virol. 2011;55(3):227-33
references.pmid: 21978156
references.citation: J Gen Virol. 2004 Oct;85(Pt 10):2981-2989
references.pmid: 15448361
references.citation: J Med Virol. 2002 Jun;67(2):207-16
references.pmid: 11992581
references.citation: Lancet. 1998 Oct 24;352(9137):1391
references.pmid: 9802304
references.citation: Arch Virol. 1979;60(3-4):329-40
references.pmid: 228639
references.citation: Vaccine. 2011 Aug 26;29(37):6269-75
references.pmid: 21722686
references.citation: J Infect Dis. 1974 Mar;129(3):304-9
references.pmid: 4361245
references.citation: J Med Virol. 2011 Oct;83(10):1783-91
references.pmid: 21837796
references.citation: PLoS One. 2012;7(12):e51996
references.pmid: 23284845
references.citation: Med Microbiol Immunol. 2013 Aug;202(4):259-65
references.pmid: 23408291
references.citation: Antiviral Res. 2013 Mar;97(3):264-9
references.pmid: 23295352
references.citation: PLoS One. 2013;8(2):e57591
references.pmid: 23451246
references.citation: J Virol. 2011 Nov;85(22):11809-20
references.pmid: 21900167
references.citation: Blood. 1996 Oct 15;88(8):3010-21
references.pmid: 8874199
references.citation: Biologicals. 1993 Dec;21(4):305-9
references.pmid: 8024744
references.citation: Clin Infect Dis. 1999 Jul;29(1):184-90
references.pmid: 10433583
references.citation: J Antimicrob Chemother. 2010 Oct;65(10):2176-82
references.pmid: 20719762
references.citation: Antiviral Res. 2005 Jul;67(1):31-7
references.pmid: 15916817
references.citation: Expert Rev Vaccines. 2012 May;11(5):609-28
references.pmid: 22827246
references.citation: J Infect Dis. 2008 Oct 1;198(7):1002-6
references.pmid: 18710325
references.citation: Clin Infect Dis. 2002 May 1;34 Suppl 2:S52-7
references.pmid: 11938497
references.citation: J Med Virol. 2012 Nov;84(11):1779-89
references.pmid: 22997081
references.citation: J Virol. 2007 Oct;81(19):10310-5
references.pmid: 17626076
references.citation: Arch Virol. 2012 Mar;157(3):539-43
references.pmid: 22187102
references.citation: Clin Infect Dis. 2001 Jan 15;32(2):228-35
references.pmid: 11170912
references.citation: Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14753-8
references.pmid: 23959904
references.citation: J Neuropathol Exp Neurol. 2008 Jun;67(6):532-42
references.pmid: 18520772
references.citation: Neuropathol Appl Neurobiol. 1982 Mar-Apr;8(2):149-56
references.pmid: 7048123
references.citation: J Virol. 2007 Sep;81(17):9386-95
references.pmid: 17567701
references.citation: Virol J. 2009 Sep 15;6:141
references.pmid: 19751532
references.citation: J Clin Virol. 2000 Jun;17(1):23-30
references.pmid: 10814935
references.citation: Arch Virol. 2012 Apr;157(4):669-79
references.pmid: 22245989
references.citation: N Engl J Med. 1999 Sep 23;341(13):929-35
references.pmid: 10498487
references.citation: Virology. 2012 Jan 5;422(1):132-43
references.pmid: 22078110
references.citation: PLoS One. 2011;6(11):e27082
references.pmid: 22069490
references.citation: Microbes Infect. 2006 Jun;8(7):1671-8
references.pmid: 16815726
references.citation: Vaccine. 2011 Mar 24;29(15):2772-6
references.pmid: 21315698
references.citation: PLoS One. 2013 Jul 30;8(7):e69858
references.pmid: 23936115
references.citation: Clin Dev Immunol. 2012;2012:876241
references.pmid: 22956971
references.citation: J Virol. 2004 Aug;78(15):7916-24
references.pmid: 15254164
references.citation: Virology. 2012 Oct 25;432(2):417-26
references.pmid: 22819834
references.citation: Clin Infect Dis. 2000 Sep;31(3):678-83
references.pmid: 11017815
references.citation: J Infect Dis. 2008 Mar 15;197(6):854-7
references.pmid: 18279075
references.citation: Respir Res. 2011 Nov 06;12:147
references.pmid: 22054060
references.citation: Vaccine. 2010 Oct 28;28(46):7444-51
references.pmid: 20831911
references.citation: Clin Microbiol Infect. 2007 Jul;13(7):677-82
references.pmid: 17441979
references.citation: Virology. 2011 Mar 30;412(1):91-100
references.pmid: 21262515
references.citation: Vaccine. 2012 Feb 8;30(7):1305-12
references.pmid: 22214888
references.citation: Genet Vaccines Ther. 2007 Apr 19;5:6
references.pmid: 17445254
references.citation: J Infect Dis. 2011 Jun 15;203(12):1784-90
references.pmid: 21536800
references.citation: Vaccine. 2011 Jun 24;29(29-30):4829-38
references.pmid: 21550375
references.citation: N Engl J Med. 2000 Feb 3;342(5):356-8
references.pmid: 10660401
references.citation: J Virol. 2007 Sep;81(17):8996-9003
references.pmid: 17567704
references.citation: Circ Res. 1981 Feb;48(2):292-8
references.pmid: 7460203
references.citation: J Virol. 2008 Feb;82(4):1787-97
references.pmid: 18057246
references.citation: Virol J. 2011 Mar 08;8:106
references.pmid: 21385398
references.citation: J Gen Virol. 2005 Dec;86(Pt 12):3263-3269
references.pmid: 16298971
references.citation: J Gen Virol. 2004 Jan;85(Pt 1):69-77
references.pmid: 14718621
references.citation: J Microbiol Immunol Infect. 2000 Dec;33(4):205-16
references.pmid: 11269363
references.citation: Mol Ther. 2007 Nov;15(11):1931-8
references.pmid: 17712333
references.citation: Lancet. 1999 Nov 13;354(9191):1682-6
references.pmid: 10568570
references.citation: N Engl J Med. 1999 Sep 23;341(13):936-42
references.pmid: 10498488
references.citation: J Biomed Sci. 2000 Nov-Dec;7(6):523-8
references.pmid: 11060501
references.citation: J Virol. 2012 Mar;86(5):2676-85
references.pmid: 22205739
references.citation: J Gen Virol. 2005 May;86(Pt 5):1391-1401
references.pmid: 15831951
references.citation: J Infect Dis. 2002 Oct 15;186(8):1161-4
references.pmid: 12355368
references.citation: Biochem Biophys Res Commun. 2013 Jan 4;430(1):387-93
references.pmid: 23159634
references.citation: FEMS Microbiol Rev. 2002 Mar;26(1):91-107
references.pmid: 12007645
references.citation: Vaccine. 2008 Feb 13;26(7):891-8
references.pmid: 18207613
references.citation: Vaccine. 2001 Dec 12;20(5-6):895-904
references.pmid: 11738755
references.citation: Nat Med. 2009 Jul;15(7):794-7
references.pmid: 19543284
references.citation: Biochem Cell Biol. 2002;80(1):1-6
references.pmid: 11908632
references.citation: J Gen Virol. 2008 Jul;89(Pt 7):1622-1632
references.pmid: 18559932
references.citation: J Crit Care. 2006 Sep;21(3):280-6
references.pmid: 16990099
references.citation: Curr Opin Virol. 2012 Apr;2(2):199-205
references.pmid: 22482716
references.citation: Emerg Infect Dis. 2001 Jan-Feb;7(1):146-8
references.pmid: 11266307
references.citation: J Clin Microbiol. 2009 Nov;47(11):3653-62
references.pmid: 19776232
references.citation: J Virol. 2012 Feb;86(4):2121-31
references.pmid: 22130542
references.citation: Lancet. 2013 Jun 8;381(9882):2024-32
references.pmid: 23726161
references.citation: Nat Med. 2009 Jul;15(7):798-801
references.pmid: 19543282
references.citation: Microbes Infect. 2011 Sep;13(10):862-70
references.pmid: 21612764
references.citation: Auton Neurosci. 2002 Nov 29;102(1-2):1-7
references.pmid: 12492129
references.citation: PLoS One. 2013;8(3):e59501
references.pmid: 23527208